Novartis Entresto® US patent upheld by US Court of Appeals
Basel, January 13, 2025 – Novartis is pleased with the decision by the US Court of Appeals for the Federal…
Idorsia to call for a bondholder meeting
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – January 13, 2025Idorsia Ltd (SIX: IDIA) today announced that…
Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel
Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon’s biosimilar candidate to Eylea®1 Agreement builds on…
Heihe Cold-Area Car Testing Index Released: Anchoring Global Innovation Hubs, Showcasing the Thriving Power of the Industry
HEIHE, China, Jan. 12, 2025 (GLOBE NEWSWIRE) — On January 8, China (Heihe) Cold-Area Car Testing Index, China’s first cold-area…
Dr. Yorell Manon Matos Launches Transformative Healthcare Education Grant to Cultivate Next Generation of Medical Innovators
Dr. Yorell Manon-Matos Dr. Yorell Manon-Matos SIOUX FALLS, S.D., Jan. 12, 2025 (GLOBE NEWSWIRE) — Distinguished hand surgeon Dr. Yorell…
Dr. Kerry Evans Award for Nursing Students: Scholarship Supporting the Future of Compassionate Patient Care
LIVINGSTON, Texas, Jan. 12, 2025 (GLOBE NEWSWIRE) — The Dr. Kerry Evans Award for Nursing Students offers an exceptional opportunity…
Dr. Abeer AbouYabis Scholarship for Future Doctors Inspires Aspiring Physicians to Tackle Healthcare Challenges
Dr. Abeer AbouYabis Dr. Abeer AbouYabis SMYRNA, Ga., Jan. 12, 2025 (GLOBE NEWSWIRE) — The prestigious Dr. Abeer AbouYabis Scholarship…
Medical Elastomer Market worth $14.27 billion by 2029, at a CAGR of 8.3 % says MarketsandMarkets™
Delray Beach, FL, Jan. 12, 2025 (GLOBE NEWSWIRE) — The Global Medical Elastomer Market size is expected to reach USD…
Arowana recognised among Real Leaders’ Top Impact Companies for 2025
Arowana ranks in the top 50 impact companies globally for the 6th year in a row For 2025 onwards, Real…
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025
— CB-010 GALLOP Phase 1 trial initiated in lupus — — CB-012 AMpLify Phase 1 trial in r/r AML completes…
Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer
New agreement enables both companies to fuel a broad and innovative pipeline of 212Pb-Radio-DARPin candidates, bringing the total number of…
Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference
Radio-DARPin MP0712 against DLL3, in co-development with Orano Med, to enter first-in-human study in 2025 Mesothelin named as second target…
↑